



## Notification of Expiry of Listed Options

**MELBOURNE Australia, 22 February 2023:** Prescient Therapeutics Limited (ASX: PTX) advises that the attached letter has been sent to registered holders of the Company's listed options (ASX: PTXOC) (**Listed Options**) advising that the Listed Options which are exercisable at \$0.0625 (6.25 cents) each will expire at 5.00pm (AEDT) on Friday, 31 March 2023 (**Expiry Date**).

Official quotation of the Listed Options on ASX will cease at close of trading on Monday, 27 March 2023, being four business days before the Expiry Date.

The attached letter outlines some of the courses of action available to holders of these soon to expire Listed Options.

**– Ends –**

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

### About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

### Cell Therapies

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

**CellPryme-M:** Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving



persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

**CellPryme-A:** CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

### **Targeted Therapies**

**PTX-100** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety.

**PTX-200** is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound is currently in a Phase 1b/2 trial in relapsed and refractory AML, where it has resulted in 4 complete remissions so far. PTX-200 previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at [www.ptxtherapeutics.com](http://www.ptxtherapeutics.com) or connect with us via Twitter [@PTX\\_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](#)

Steven Yatomi-Clarke  
CEO & Managing Director  
Prescient Therapeutics  
[steven@ptxtherapeutics.com](mailto:steven@ptxtherapeutics.com)

**Investor enquiries:**  
Sophie Bradley – Reach Markets  
+61 450 423 331  
[ir@reachmarkets.com.au](mailto:ir@reachmarkets.com.au)

**Media enquiries:**  
Andrew Geddes – CityPR  
+61 2 9267 4511  
[ageddes@citypublicrelations.com.au](mailto:ageddes@citypublicrelations.com.au)



22 February 2023

Dear Option Holder,

### EXPIRY OF LISTED PTXOC OPTIONS

Prescient Therapeutics Limited (ASX:PTX) (**Company**) is writing to you as a registered holder of PTXOC Listed Options (**Options**) to remind you that the Options will expire at 5.00pm (AEDT) on Friday, 31 March 2023 (**Expiry Date**).

The Options are due to expire on Friday, 31 March 2023 and may be exercised in whole or in part by payment of \$0.0625 (6.25 cents) for each Option. If payment is not received by 5:00pm (AEDT) on Friday, 31 March 2023, the Options will lapse and all rights under the Options will cease at that time. On exercise, each Option entitles the holder to receive one fully paid ordinary share (**Share**) in the Company.

Some of the courses of action available to you as a holder of these soon to expire Options are:

#### (a) Exercise your Options

If you wish to exercise your Options, you must complete the "Notice of Exercise of Options" (**Notice of Exercise**) form accompanying this letter and provide the completed Notice of Exercise together with payment of \$0.0625 (6.25 cents) per Option being exercised in accordance with the instruction set out in the Notice of Exercise. Your completed Notice of Exercise and payment (in cleared funds) must be received by the Expiry Date.

#### (b) Sell your Options

Please note that official quotation of the Options on the Australian Securities Exchange (**ASX**) will cease at close of trading on Monday, 27 March 2023.

#### (c) Do nothing and allow your Options to expire

If you do not exercise or sell your Options in the manner described above, they will expire on the Expiry Date and your right to subscribe for fully paid ordinary shares in the capital of the Company (**Shares**) at \$0.0625 (6.25 cents) per Share will lapse.

There is no obligation on option holders to exercise their Options. However, in accordance with clause 5.2 of Appendix 6A of the ASX Listing Rules, the Company is required to advise option holders of the information contained in this notice:

1. The name of the option holder is contained in the enclosed personalised Notice of Exercise.
2. The number of Options held, and the number of fully paid ordinary shares in the Company to be issued on the conversion of the Options are contained in the enclosed personalised Notice of Exercise for the option holder. These Options entitle you to acquire one fully paid ordinary share in the capital of the Company for each Option you choose to exercise.



3. The exercise price of these Options is \$0.0625 (6.25 cents) each.
4. The due date for payment is the Expiry Date, being 5.00pm (AEDT) on Friday, 31 March 2023.
5. There is no obligation upon the option holder to exercise their Options however if payment is not received by the Expiry Date the Options will lapse and all rights under the Options will cease at that time.
6. The Options will cease to be quoted on ASX from close of trading on Monday, 27 March 2023.
7. The market price for Shares in the Company on the ASX was A\$0.095 on 21 February 2023, being the last trading day in the Company prior to the date of this letter.
8. During the three months preceding the date of this notice the highest market price of Shares in the Company on the ASX was A\$0.160 on 7 December 2022 and the lowest market price was A\$0.085 on 7 February 2023.
9. The Board confirms that there is no underwriting agreement in place for the exercise of the Options.

If you have any questions regarding the exercise of your Options, please do not hesitate to contact our Automic Group on 1300 288 664 (within Australia) or +61 2 9698 5414 (Overseas) or email [corporate.actions@automicgroup.com.au](mailto:corporate.actions@automicgroup.com.au).

Yours Faithfully,

A handwritten signature in black ink, appearing to read "Melanie Leydin".

Melanie Leydin  
Company Secretary  
**Prescient Therapeutics Limited**


SRN/HIN: [HolderNumberMasked]
Security Code: PTXOC
Number of Options held: [PTXOCHolding]
<b>Option Expiry Date: 31 March 2023</b>
<b>Exercise Price: \$0.0625</b>
Total Amount payable (exercising in full): [Pay]

## Notice of Exercise of Options

You can exercise your Options by paying \$0.0625 per Option in accordance with section 2 below by 31 March 2023.

By making a BPAY® or EFT payment, you hereby exercise the following number of Options and make payment in Australian currency for the amount payable. You will be allotted Ordinary Shares calculated on the basis of one (1) Ordinary Share for every one (1) Option exercised. You agree to accept such Shares subject to the Constitution of Prescient Therapeutics Limited.

<b>1. Number of Options to be Exercised</b> <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/>	<b>Total payment required @ \$0.0625 per Option</b> A\$ <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>
If the dollar amount paid results in a fraction of a share then the shares allotted will be rounded down.	

<b>2. Payment: You can pay either by BPAY® or EFT</b>	
<b>Option A – BPAY®</b>  <b>Biller Code:</b> <b>Ref No:</b> <small>© Registered to BPAY Pty Ltd ABN 69079137518</small>	<b>Option B – Electronic Funds Transfer (EFT)</b> The unique payment reference number which has been assigned to your Application is: [holderId]-[CAId]-PTXOC Funds are to be deposited directly to following bank account: <b>Account name:</b> Automic Pty Ltd <b>Account BSB:</b> <b>Account number:</b> <b>Swift Code:</b> <b>IMPORTANT:</b> You must quote your unique reference number as your payment reference/ description when processing your EFT payment. Failure to do so may result in your funds not being allocated to exercise the Options and shares subsequently not issued. <b>Note: You do not need to return this Form if you have made payment via EFT. Your unique payment reference number will process your payment to your Options exercise electronically.</b>
Contact your financial institution to make your payment from your cheque or savings account. <b>Note: You do not need to return this form if you have made payment via BPAY®. Your BPAY® reference number will process your payment to your Options exercise electronically.</b> You should check the processing cut-off time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Share Registry in time.	

<b>3. Contact details</b>	
Telephone Number <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	Contact Name (PLEASE PRINT) <input type="text"/>
Email Address <input type="text"/>	
<b>SUPPORT YOUR COMPANY:</b> By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).	